Related Experiment Videos
Treatment of scleroderma
Allen N Sapadin1, Raul Fleischmajer
1Department of Dermatology, Mount Sinai School of Medicine, 1425 Madison Ave, PO Box 1047, New York, NY 10029, USA.
Archives of Dermatology
|January 16, 2002
Summary
Treating systemic sclerosis (scleroderma) is challenging. This review analyzes current and emerging therapies, including vasodilators, immunosuppressants, antifibrotics, and novel treatments for scleroderma.
Area of Science:
- Rheumatology
- Dermatology
- Immunology
Background:
- Systemic sclerosis (scleroderma) presents significant clinical challenges due to its unknown etiology.
- Current therapeutic strategies aim to improve circulation, modulate immune responses, and reduce fibrosis.
Purpose of the Study:
- To critically review conventional and novel treatment options for systemic sclerosis and localized scleroderma.
- To provide an overview of established and investigational therapies.
Main Methods:
- Literature review of established and emerging treatments for systemic sclerosis and localized scleroderma.
- Analysis of therapeutic agents including vasodilators, immunosuppressants, antifibrotics, and newer agents.
Main Results:
- Conventional treatments for systemic sclerosis involve vasodilators (e.g., nifedipine), immunosuppressants (e.g., methotrexate), and antifibrotics (e.g., D-penicillamine).
- Localized scleroderma treatments include corticosteroids, vitamin D analogues, and UV-A therapy.
- Emerging therapies for systemic sclerosis show promise, including minocycline, stem cell transplantation, and etanercept.
Conclusions:
- A comprehensive understanding of current and novel therapies is crucial for managing systemic sclerosis and localized scleroderma.
- Further research into emerging treatments is warranted to improve patient outcomes.